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Abstract Interferon regulatory factor-1 (IRF-1) is a transcrip-
tional activator that is involved in interferon response, regula-
tion of cell growth and oncogenesis. To try to identify the mol-
ecules that regulate the function of IRF-1, we performed yeast
two-hybrid screening and isolated protein inhibitor of activated
STAT3 (PIAS3) as an IRF-1-binding protein. This protein was
also found to bind with small ubiquitin-related modi¢er-1
(SUMO-1) and ubiquitin-conjugating enzyme 9, an E2 in the
SUMO-1-conjugating system. Co-expression of PIAS3 induced
SUMO-1 modi¢cation of IRF-1 in a RING ¢nger domain-de-
pendent manner and also repressed transcriptional activity of
IRF-1. Thus, PIAS3 functions as a SUMO-1 ligase for IRF-1
and also as a repressor of IRF-1 transcriptional activity.
2 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Interferon regulatory factor-1 (IRF-1), which has been
identi¢ed as a transcriptional activator of interferon-L [1],
regulates the expression of various genes involved in anti-viral
and anti-bacterial immune responses, is involved in DNA
damage-induced cell cycle arrest in collaboration with the tu-
mor suppressor p53 through induction of CDK inhibitor
p21Cip1=Waf1, and functions as a negative regulator of cell
growth [2]. In addition, analyses of IRF-1/p53 double null
mice and patients with acute myeloid leukemia and myelodys-
plasia suggest that IRF-1 has a tumor-suppressing activity [2].
Small ubiquitin-related modi¢er-1 (SUMO-1) is a protein
that shares 18% identity with ubiquitin and is covalently con-
jugated to target proteins by a system analogous to the ubiq-
uitin conjugation system: SUMO-1 is activated by E1 enzyme
(Aos1/Uba2 heterodimer) in an ATP-dependent manner, is
transferred to E2 enzyme (ubiquitin-conjugating enzyme 9,
Ubc9), and then attaches to O-amino groups of speci¢c lysine
residues of target proteins [3^5]. Recently, four members of
the mammalian PIAS (protein inhibitor of activated STAT)
family, PIAS1, PIASxK, PIASxL and PIASy, and a yeast
PIAS homologue, Siz1, have been reported to have SUMO-
1 ligase activities toward various target proteins, including
p53, androgen receptor, LEF1 and septin [6^12]. In addition,
it has been shown that PIAS-mediated SUMO-1 modi¢cation
of various transcription factors causes up- or down-regulation
of their transcriptional activity [8,11,12].
We previously reported that the stability of IRF-1 is gov-
erned by the ubiquitin^proteasome system [13]. In a search for
proteins that regulate the function and the stability of IRF-1,
we identi¢ed PIAS3 and Ubc9 as IRF-1-binding proteins. In
the present study, we found that PIAS3 mediates SUMO-1
modi¢cation of IRF-1 and suppresses IRF-1 transcriptional
activity in a RING ¢nger domain-dependent manner. To the
best of our knowledge, this is the ¢rst report on PIAS3 as a
SUMO-1 ligase for the speci¢c target protein. We propose
that the function of IRF-1 is regulated by PIAS3 through
its SUMO-1 ligase activity.
2. Materials and methods
2.1. Cell culture and transfection
Human embryonic kidney 293T cells were cultured in Dulbecco’s
modi¢ed Eagle’s medium (Sigma) supplemented with 10% fetal bovine
serum (Gibco) and antibiotics at 37‡C under 5% CO2 atmosphere.
Transfection was performed using FuGENE6 (Roche) according to
the manufacturer’s protocol.
2.2. Plasmid construction
Mouse IRF-1 cDNA [13] was subcloned into the pCI-neo-FLAG
plasmid [13], and a fragment containing FLAG-tagged IRF-1 from
pCI-neo-FLAG-IRF-1 was subcloned into the pEF-BOS vector (a gift
from Dr. S. Nagata of Osaka University) [14] to construct a mamma-
lian expression plasmid of IRF-1, pEF-FLAG-IRF-1. The open read-
ing frames of PIAS3 and UBC9 were ampli¢ed by polymerase chain
reaction (PCR) with the respective cDNAs obtained from positive
clones in yeast two-hybrid screening as templates. The resulting
PCR fragment of PIAS3 was subcloned into the pCI-neo-6Myc vector
that had been generated by inserting a fragment containing six copies
of the Myc epitope into the pCI-neo mammalian expression vector
(Promega). Deletion mutants of PIAS3 were generated by PCR and
subcloned into the pAD-Gal4 vector (Stratagene). The PIAS3 (C334S)
mutant was generated using a QuickChange Site-Directed Mutagene-
sis kit (Stratagene) and subcloned into the pCI-neo-6Myc vector.
pGLex, the LexA-derived bait vector for a yeast two-hybrid assay,
and pCGT-T7-SUMO-1, a SUMO-1 mammalian expression plasmid,
were gifts from Dr. H. Ariga of Hokkaido University. UBC9 and
SUMO-1 cDNAs were subcloned into the pGLex vector for yeast
two-hybrid analysis.
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2.3. Yeast two-hybrid screening
pGLex-IRF-1 (1^190) was constructed by fusing the IRF-1 (1^190)
coding sequence in-frame to the LexA DNA-binding domain in the
pGLex vector. Saccharomyces cerevisiae L40 cells transformed with
pGLex-IRF-1 (1^190) and a mouse embryonic ¢broblast MATCH-
MAKER cDNA library (Clontech) were plated onto media that
lacked tryptophan, leucine and histidine and had been supplemented
with 5 mM 3-amino-1,2,4-triazole (Sigma). Approximately 1.5U106
colonies were screened for growth in the absence of histidine and for
LacZ expression. The activity of L-galactosidase was determined using
X-gal as a substrate. Plasmid DNAs derived from double-positive
clones were extracted from yeasts, and the nucleotide sequences
were determined using an ABI Prism 377 DNA sequencer (Perkin-
Elmer).
2.4. Immunoprecipitation and immunoblotting
Human 293T cells were transiently transfected with the indicated
plasmids using FuGENE6, and at 36 h after transfection, the cells
were treated with 10 WM MG132 (Peptide Institute, Osaka, Japan) for
4 h to inhibit proteasomal degradation of IRF-1. After the cells had
been washed with ice-cold phosphate-bu¡ered saline, they were lysed
with a bu¡er containing 50 mM Tris^HCl, pH 7.5, 0.3 M NaCl, 0.5%
Triton X-100, complete protease inhibitor cocktail (Roche), 10 mM
N-ethylmaleimide (Sigma) and 50 WM MG132. The cell lysate was
sonicated for 10 s and the debris was removed by centrifugation at
13 000Ug for 20 min. The resulting supernatant was incubated with
anti-FLAG M2 a⁄nity gel (Sigma) for 2 h at 4‡C, and the immuno-
complex produced was washed ¢ve times with lysis bu¡er. For West-
ern blotting, the whole cell lysate and immunoprecipitates were sepa-
rated by SDS^PAGE and transferred onto nitrocellulose membranes
(Bio-Rad). The membranes were immunoblotted with anti-T7 (Nova-
gen), anti-Myc (9E10, Santa Cruz) and anti-IRF-1 (Santa Cruz) anti-
bodies and incubated with horseradish peroxidase-conjugated anti-
bodies against mouse or rabbit immunoglobulin (Amersham),
followed by detection with ECL Western blotting detection reagents
(Amersham).
2.5. Reporter gene assay
Human 293T cells seeded onto 24-well dishes were transfected with
the pISRE-Luc reporter plasmid (Clontech) and with combinations of
IRF-1 and wild-type PIAS3 or PIAS3 C334S mutant expression plas-
mids, together with phRG-TK (Promega) for normalizing transfection
e⁄ciency. The total amounts of plasmids were adjusted with empty
vectors pCI-neo and pEF-BOS. Twenty-four hours after transfection,
luciferase activity was measured by using a Dual-Luciferase Reporter
Assay System (Promega) and an AB-2000 luminescencer-PSN (Atto,
Tokyo, Japan). The same experiments were repeated three times.
3. Results and discussion
3.1. PIAS3 is an IRF-1-binding protein
To identify proteins that regulate the function of IRF-1, we
Fig. 1. PIAS3 is capable of interacting with IRF-1. A: Protein interaction in a yeast two-hybrid system. Yeast L40 cells were transformed with
the indicated expression vectors containing IRF-1 (1^190) fused to the LexA DNA-binding domain (DBD) and PIAS3 fused to the GAL4 acti-
vation domain (GAD). L-Galactosidase activity of each transformant was measured. B: Interaction of IRF-1 and PIAS3 in mammalian cells.
293T cells were transiently transfected with expression vectors containing FLAG-tagged IRF-1 and Myc-tagged PIAS3 as indicated. Cell lysate
was subjected to immunoprecipitation (IP) with anti-FLAG antibody, and the resulting precipitates were subjected to immunoblotting (IB) with
anti-Myc and anti-IRF-1 antibodies. A portion of the cell lysate was directly subjected to IB with anti-Myc antibody in order to verify the ex-
pression level of PIAS3 protein. C: Schematic representation of various PIAS3 constructs. PIAS3 contains a putative chromatin-binding SAP
(SAF-A/B, Acinus and PIAS) domain, a RING ¢nger domain and a Ser/Ac (serine- and acidic amino acid-rich) domain. D: Interaction of
IRF-1 with PIAS3 deletion mutants in yeast. L40 cells were transformed with the indicated expression vectors containing IRF-1 (1^190) fused
to LexA DBD and various deletion constructs of PIAS3 fused to GAD. L-Galactosidase activity of each transformant was measured.
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performed yeast two-hybrid screening with a mouse embry-
onic ¢broblast cDNA library using the N-terminal region
(amino acids 1^190) of IRF-1 as bait (Fig. 1A). A screen of
approximately 1.5U106 yeast transformants yielded 20 colo-
nies that grew in selective media and expressed LacZ. DNA
sequencing analysis revealed that four of these clones were
identical to a long form of PIAS3 [15] that contains a 105-
bp (35-amino acid) insertion in the N-terminal region (Gen-
Bank accession number BC023128).
We next carried out an experiment to determine whether
IRF-1 is capable of associating with PIAS3 in mammalian
cells. FLAG-tagged IRF-1 and Myc-tagged PIAS3 were tran-
siently expressed in 293T cells and the cell extract was pre-
pared. The extract was subjected to immunoprecipitation us-
ing anti-FLAG antibody, and the co-immunoprecipitated
PIAS3 was detected by immunoblotting with anti-Myc anti-
body. As shown in Fig. 1B, PIAS3 was co-immunoprecipi-
tated with IRF-1. These results indicate that IRF-1 and
PIAS3 are capable of forming a complex in mammalian cells.
To determine the domain of PIAS3 required for its inter-
action with IRF-1, we constructed various deletion mutants of
PIAS3 (Fig. 1C) and fused them to the Gal4 activation do-
main. Yeast two-hybrid analysis using IRF-1 (1^190) as bait
revealed that the serine- and acidic amino acid-rich domain
(Ser/Ac domain) in the C-terminal region of PIAS3 is respon-
sible for the association with IRF-1 (Fig. 1D).
3.2. PIAS3 mediates SUMO-1 modi¢cation of IRF-1
In the yeast two-hybrid screening described above, Ubc9
was also identi¢ed as a binding partner of IRF-1 (data not
shown). Ubc9 functions as an E2 in the SUMO-1-conjugating
system [3^5]. In addition, it has recently been reported that
PIAS3 interacts with Ubc9 and SUMO-1 in vitro [11]. Our
results of yeast two-hybrid analysis also indicated that PIAS3
interacts with Ubc9 and SUMO-1 in yeast (Fig. 2A). From
these results, we speculated that PIAS3 has SUMO-1 ligase
activity toward IRF-1. To con¢rm this possibility, we transi-
ently expressed FLAG-tagged IRF-1, T7-tagged SUMO-1 and
Myc-tagged PIAS3 in 293T cells. The cell extract was sub-
jected to immunoprecipitation with anti-FLAG antibody,
and the immunoprecipitates produced were probed by West-
ern blotting with anti-T7 or anti-IRF-1 antibody (Fig. 2B).
One band with slower mobility than that of intact IRF-1 was
detected by anti-IRF-1 antibody only in the case of co-trans-
fection with FLAG-IRF-1, T7-SUMO-1 and Myc-PIAS3 ex-
pression plasmids, and this band was also detected with anti-
T7 antibody. These results suggest that IRF-1 is conjugated
with SUMO-1, the conjugation being mediated by PIAS3.
Furthermore, in immunoblotting of cell lysate with anti-Myc
antibody, two bands with slower mobilities than that of intact
PIAS3 were detected only in the presence of SUMO-1, sug-
gesting that PIAS3 is also conjugated with SUMO-1, the con-
jugation being mediated by PIAS3 itself. This is consistent
with the previous reports on SUMO-1 modi¢cation of other
PIAS family proteins by themselves [11,12]. Thus, PIAS3 me-
diates SUMO-1 modi¢cation of IRF-1 and of itself.
3.3. PIAS3 functions as a SUMO-1 ligase
PIAS family proteins contain a RING ¢nger domain called
Fig. 2. PIAS3 mediates SUMO-1 modi¢cation of IRF-1. A: Interac-
tion of PIAS3 with Ubc9 and SUMO-1. A yeast two-hybrid assay
was performed as described in Fig. 1A. B: SUMO-1 modi¢cation of
IRF-1 by PIAS3 in vivo. 293T cells were transiently transfected
with expression vectors containing FLAG-tagged IRF-1, T7-tagged
SUMO-1 and Myc-tagged PIAS3 as indicated. Cell lysate was sub-
jected to immunoprecipitation (IP) and then to immunoblotting (IB)
as described in Fig. 1B. A portion of the cell lysate was directly
subjected to IB with anti-T7 and anti-Myc antibodies in order to
verify the expression levels of SUMO-1 and PIAS3 proteins, respec-
tively. Ig (H), heavy chain of immunoglobulin.
Fig. 3. The RING ¢nger domain of PIAS3 is required for SUMO-1
modi¢cation of IRF-1. 293T cells were transiently transfected with
expression vectors containing FLAG-tagged IRF-1, T7-tagged
SUMO-1 and Myc-tagged wild-type or C334S mutant of PIAS3 as
indicated. Cell lysate was subjected to immunoprecipitation (IP) and
then to immunoblotting (IB) as described in Fig. 1B. A portion of
the cell lysate was directly subjected to IB as described in Fig. 2B.
Ig (H), heavy chain of immunoglobulin.
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the SP-RING (Siz/PIAS RING) domain [16], which is essen-
tial for binding of PIAS to Ubc9 and for SUMO-1 ligase
activity [6^12]. To determine the requirement of the RING
¢nger domain of PIAS3 for SUMO-1 modi¢cation of IRF-1,
we constructed a point mutant, PIAS3 (C334S), in which the
conserved cysteine residue in the RING ¢nger domain had
been changed to serine [7,17], and we performed co-transfec-
tion experiments followed by immunoprecipitation (Fig. 3).
Although the C334S mutant was co-precipitated with IRF-1,
co-expression of PIAS3 (C334S) and SUMO-1 in 293T cells
did not enhance SUMO-1 conjugation of IRF-1, in contrast
to the case with wild-type PIAS3. In addition, immunoblot-
ting of cell lysate with anti-Myc antibody showed that PIAS3
(C334S) also failed to enhance SUMO-1 modi¢cation of the
mutant itself. Thus, the RING ¢nger domain of PIAS3 is
essential for SUMO-1 modi¢cation of IRF-1 and PIAS3, sug-
gesting that PIAS3 functions as a SUMO-1 ligase.
It has been demonstrated that SUMO-1 is conjugated to the
speci¢c lysine residue in the consensus sequence (8KXE; 8,
hydrophobic amino acid) in many, but not all, target proteins
[3^5]. On the other hand, recent studies have indicated that
this sequence is a binding site for Ubc9 in the case of Ran-
GAP1 in vitro [18,19]. IRF-1 lacks the above consensus se-
quence, although this protein is conjugated with SUMO-1.
Studies to identify the SUMO-1 conjugation sites in IRF-1
are now in progress in our laboratory.
3.4. PIAS3 represses transcriptional activity of IRF-1
Next, we carried out an experiment to determine whether
PIAS3 modulates transcriptional activity of IRF-1. 293T cells
were co-transfected with IRF-1 and wild-type PIAS3 or
PIAS3 (C334S) mutant expression plasmids together with a
reporter gene containing ISRE (interferon-stimulated response
element), which is known to be a binding sequence for the
IRF family [2], and luciferase activity was measured (Fig. 4).
Wild-type PIAS3 suppressed the transcriptional activity of
IRF-1 in a dose-dependent manner, while the PIAS3
(C334S) mutant exhibited weaker suppressive activity than
did the wild-type. Similar results were obtained when human
HepG2 cells were used in place of 293T cells (data not
shown). These results suggest that the suppressive action of
PIAS3 on IRF-1 transcriptional activity is partially dependent
on its SUMO-1 ligase activity.
PIAS3 was originally identi¢ed as a transcriptional repres-
sor of activated STAT3 [15] and subsequently as a binding
protein of other transcriptional regulators such as androgen
receptor [20^22], G¢-1 [23], HMG-1C [24] and MITF [25].
Co-expression of PIAS3 up- or down-regulates the activities
of these transcription factors, although it is not known how
PIAS3 regulates these transcriptional activities. It has recently
been reported that PIASy represses the activity of the tran-
scription factor LEF1 by targeting LEF1 into nuclear bodies
in a RING ¢nger domain-dependent manner [8]. In connec-
tion with this, it should be noted that SUMO-1 modi¢cation
is required for the nuclear body localization of various nuclear
proteins [3^5]. PIAS3 has been reported to be located in nu-
clear bodies [11,23] and we found in the present study that
SUMO-1 ligase activity of PIAS3 is partly responsible for its
repressive action on IRF-1 activity. On the other hand,
PIAS3, as well as PIAS1, has been reported to function as a
direct inhibitor of DNA binding of STAT in vitro [15,17].
Taken together, the results suggest that PIAS3 may negatively
regulate the activity of IRF-1 by sequestering IRF-1 to nu-
clear bodies through PIAS3-mediated SUMO-1 modi¢cation,
while PIAS3 may also regulate IRF-1 activity through a
SUMO-1-independent mechanism, such as direct inhibition
of DNA binding of IRF-1. Further detailed analysis is needed
to elucidate the mechanism by which PIAS3 regulates tran-
scriptional activity of IRF-1.
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